Acute Stroke: Commercial risk offsets high unmet need

Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.

In the setting of acute stroke, a patient's treatment options and recovery prospects are a function of time. Therefore any delay related to the time-to-treatment constitutes a resistor to market entry and uptake for stroke therapies in the acute care hospital setting.

The R&D landscape is shaped by the need to minimize the commercial risk associated with developing drugs for the acute-care stroke market - the majority of the companies contribute only one candidate drug to the acute stroke pipeline.

The future prognosis for the acute stroke therapy is marred by the long list of failures, especially of neuroprotectants. Thrombolytics are also plagued by shortcomings in trial design, which result either in discontinuation of the drugs, or prolonged development that leads in its turn to the low credibility of the compounds.

Read more...

• Therapeutic Vaccines (17/08/2010)
• Authorized Generic Pharmaceuticals (29/06/2010)
• Type 1 Diabetes (28/06/2010)

• Online Patient Recruitment (10/06/2008)
• Pricing & Reimbursement (10/06/2008)
• Postmarketing Clinical Research (10/06/2008)
• Contract Manufacturing Strategies (10/06/2008)
• Chinese Pharmaceutical Market Overview (27/05/2008)
• Antithrombotics (27/05/2008)
• Migraine (27/05/2008)
• Gynecological Cancers (27/05/2008)
• Pricing and Reimbursement in Oncology (27/05/2008)

---